BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 18854871)

  • 1. Multiple giant cell lesions in patients with Noonan syndrome and cardio-facio-cutaneous syndrome.
    Neumann TE; Allanson J; Kavamura I; Kerr B; Neri G; Noonan J; Cordeddu V; Gibson K; Tzschach A; Krüger G; Hoeltzenbein M; Goecke TO; Kehl HG; Albrecht B; Luczak K; Sasiadek MM; Musante L; Laurie R; Peters H; Tartaglia M; Zenker M; Kalscheuer V
    Eur J Hum Genet; 2009 Apr; 17(4):420-5. PubMed ID: 18854871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardio-facio-cutaneous and Noonan syndromes due to mutations in the RAS/MAPK signalling pathway: genotype-phenotype relationships and overlap with Costello syndrome.
    Nava C; Hanna N; Michot C; Pereira S; Pouvreau N; Niihori T; Aoki Y; Matsubara Y; Arveiler B; Lacombe D; Pasmant E; Parfait B; Baumann C; Héron D; Sigaudy S; Toutain A; Rio M; Goldenberg A; Leheup B; Verloes A; Cavé H
    J Med Genet; 2007 Dec; 44(12):763-71. PubMed ID: 17704260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SOS1 is the second most common Noonan gene but plays no major role in cardio-facio-cutaneous syndrome.
    Zenker M; Horn D; Wieczorek D; Allanson J; Pauli S; van der Burgt I; Doerr HG; Gaspar H; Hofbeck M; Gillessen-Kaesbach G; Koch A; Meinecke P; Mundlos S; Nowka A; Rauch A; Reif S; von Schnakenburg C; Seidel H; Wehner LE; Zweier C; Bauhuber S; Matejas V; Kratz CP; Thomas C; Kutsche K
    J Med Genet; 2007 Oct; 44(10):651-6. PubMed ID: 17586837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: molecular diversity and associated phenotypic spectrum.
    Sarkozy A; Carta C; Moretti S; Zampino G; Digilio MC; Pantaleoni F; Scioletti AP; Esposito G; Cordeddu V; Lepri F; Petrangeli V; Dentici ML; Mancini GM; Selicorni A; Rossi C; Mazzanti L; Marino B; Ferrero GB; Silengo MC; Memo L; Stanzial F; Faravelli F; Stuppia L; Puxeddu E; Gelb BD; Dallapiccola B; Tartaglia M
    Hum Mutat; 2009 Apr; 30(4):695-702. PubMed ID: 19206169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutation analysis of the genes involved in the Ras-mitogen-activated protein kinase (MAPK) pathway in Korean patients with Noonan syndrome.
    Lee ST; Ki CS; Lee HJ
    Clin Genet; 2007 Aug; 72(2):150-5. PubMed ID: 17661820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Case report: Noonan syndrome with multiple giant cell lesions and review of the literature.
    Karbach J; Coerdt W; Wagner W; Bartsch O
    Am J Med Genet A; 2012 Sep; 158A(9):2283-9. PubMed ID: 22848035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Noonan and cardio-facio-cutaneous syndromes: two clinically and genetically overlapping disorders.
    Nyström AM; Ekvall S; Berglund E; Björkqvist M; Braathen G; Duchen K; Enell H; Holmberg E; Holmlund U; Olsson-Engman M; Annerén G; Bondeson ML
    J Med Genet; 2008 Aug; 45(8):500-6. PubMed ID: 18456719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new mutation in the C-SH2 domain of PTPN11 causes Noonan syndrome with multiple giant cell lesions.
    Carapito R; Paul N; Untrau M; Ott L; Corradini N; Poignant S; Geffroy L; Caldagues E; Heymann MF; Cassagnau E; Isidor B; Bahram S
    J Hum Genet; 2014 Jan; 59(1):57-9. PubMed ID: 24225993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SOS1 and PTPN11 mutations in five cases of Noonan syndrome with multiple giant cell lesions.
    Beneteau C; Cavé H; Moncla A; Dorison N; Munnich A; Verloes A; Leheup B
    Eur J Hum Genet; 2009 Oct; 17(10):1216-21. PubMed ID: 19352411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Noonan, Costello and cardio-facio-cutaneous syndromes: dysregulation of the Ras-MAPK pathway.
    Tidyman WE; Rauen KA
    Expert Rev Mol Med; 2008 Dec; 10():e37. PubMed ID: 19063751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spectrum of MEK1 and MEK2 gene mutations in cardio-facio-cutaneous syndrome and genotype-phenotype correlations.
    Dentici ML; Sarkozy A; Pantaleoni F; Carta C; Lepri F; Ferese R; Cordeddu V; Martinelli S; Briuglia S; Digilio MC; Zampino G; Tartaglia M; Dallapiccola B
    Eur J Hum Genet; 2009 Jun; 17(6):733-40. PubMed ID: 19156172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and molecular analysis of RASopathies in a group of Turkish patients.
    Şimşek-Kiper PÖ; Alanay Y; Gülhan B; Lissewski C; Türkyilmaz D; Alehan D; Cetin M; Utine GE; Zenker M; Boduroğlu K
    Clin Genet; 2013 Feb; 83(2):181-6. PubMed ID: 22420426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical manifestations in patients with SOS1 mutations range from Noonan syndrome to CFC syndrome.
    Narumi Y; Aoki Y; Niihori T; Sakurai M; Cavé H; Verloes A; Nishio K; Ohashi H; Kurosawa K; Okamoto N; Kawame H; Mizuno S; Kondoh T; Addor MC; Coeslier-Dieux A; Vincent-Delorme C; Tabayashi K; Aoki M; Kobayashi T; Guliyeva A; Kure S; Matsubara Y
    J Hum Genet; 2008; 53(9):834-841. PubMed ID: 18651097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigation of gene dosage imbalances in patients with Noonan syndrome using multiplex ligation-dependent probe amplification analysis.
    Nyström AM; Ekvall S; Thuresson AC; Denayer E; Legius E; Kamali-Moghaddam M; Westermark B; Annerén G; Bondeson ML
    Eur J Med Genet; 2010; 53(3):117-21. PubMed ID: 20302979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive genetic analysis of overlapping syndromes of RAS/RAF/MEK/ERK pathway.
    Tumurkhuu M; Saitoh M; Sato A; Takahashi K; Mimaki M; Takita J; Takeshita K; Hama T; Oka A; Mizuguchi M
    Pediatr Int; 2010 Aug; 52(4):557-62. PubMed ID: 20030748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Molecular genetic diagnostics in syndromes associated with the RAS/MAPK signalling pathway].
    Molven A; Søvik O; von der Lippe C; Steine SJ; Njølstad PR; Houge G; Prescott TE
    Tidsskr Nor Laegeforen; 2009 Nov; 129(22):2358-61. PubMed ID: 19935936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of germline mutations in the Ras/MAPK signaling pathway on adaptive behavior: cardiofaciocutaneous syndrome and Noonan syndrome.
    Pierpont EI; Pierpont ME; Mendelsohn NJ; Roberts AE; Tworog-Dube E; Rauen KA; Seidenberg MS
    Am J Med Genet A; 2010 Mar; 152A(3):591-600. PubMed ID: 20186801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PTPN11, SOS1, KRAS, and RAF1 gene analysis, and genotype-phenotype correlation in Korean patients with Noonan syndrome.
    Ko JM; Kim JM; Kim GH; Yoo HW
    J Hum Genet; 2008; 53(11-12):999-1006. PubMed ID: 19020799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-occurring SHOC2 and PTPN11 mutations in a patient with severe/complex Noonan syndrome-like phenotype.
    Ekvall S; Hagenäs L; Allanson J; Annerén G; Bondeson ML
    Am J Med Genet A; 2011 Jun; 155A(6):1217-24. PubMed ID: 21548061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PTPN11 and KRAS gene analysis in patients with Noonan and Noonan-like syndromes.
    Brasil AS; Pereira AC; Wanderley LT; Kim CA; Malaquias AC; Jorge AA; Krieger JE; Bertola DR
    Genet Test Mol Biomarkers; 2010 Jun; 14(3):425-32. PubMed ID: 20578946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.